1. Individualizing Prophylaxis in Hemophilia

2. Program Goals

3. Joint Bleeding and Progression of Joint Damage

4. Preventing Joint Bleeding in Hemophilia Prophylactic Factor Replacement Therapy

5. Prophylaxis Swedish Experience

6. Prophylaxis Swedish Experience (cont)

7. Joint Disease and Annual Joint Bleeding Rate

8. Orthopedic Outcome Study

9. Orthopedic Outcome Study (cont)

11. Joint Outcome Study Summary of Results

13. Canadian Dose-Escalation Study

14. Canadian Dose-Escalation Study Potential Effect of Subclinical Bleeding on Joint Status

15. Comparison of MRI, Orthopedic, and Radiologic Joint Scores in Young Boys With Hemophilia

16. Comparison of MRI, Orthopedic, and Radiologic Joint Scores in Young Boys With Hemophilia (cont)

18. When Should Prophylaxis Be Initiated?

19. Which Patients Should Be Receiving Prophylaxis?

20. Does Prophylaxis Put Patients at Risk for Inhibitors?

21. Which Factor Products Can Be Used for Prophylaxis?

22. Use of New Extended Half-life Factor VIII and Factor IX in Prophylaxis

23. How to Evaluate Whether Prophylaxis Is Working

24. Monitoring Patients Receiving Prophylaxis

26. What Is an Optimal Factor Level to Prevent Bleeding?

27. Joint Bleeding and Hemophilia Severity

28. Methods Used to Measure Patient Adherence to Prophylaxis

29. Adherence to Prophylaxis

30. Adherence to Prophylaxis in Severe Hemophilia Nurse Survey

31. On-demand and Prophylactic Treatment Across Age Groups in Severe Hemophilia A Nurse Survey

32. Patient-reported Reasons for Nonadherence

33. Consequences of Poor Adherence to Hemophilia Treatment

34. Summary

35. Abbreviation

36. References

37. References (cont)

38. References (cont)

39. References (cont)

40. References (cont)

41. References (cont)

42. References (cont)